At the end of the third quarter 2012, Merck had 39,545 employees worldwide, compared to 40,676 on December 31, 2011.
Merck Group | Number of employees as of Sept. 30, 2012: 39,545
From a regional perspective, North America generated healthy organic sales growth of 12.8%, expanding its contribution to 21% of Group sales (Q3 2011: 18%), as a result of strong sales from Merck Serono, particularly the Multiple Sclerosis drug Rebif®, as well as from high demand from Merck Millipore’s biopharmaceutical customers. Emerging Markets, which consists of Latin America and Asia excluding Japan, represented 35% of Group sales in the third quarter of 2012 (Q3 2011: 33%) and reported 12.0% organic sales growth. The Rest of World segment, which is Japan, Africa, and Australia/Oceania, generated 9% of Group sales (Q3 2011: 9%), growing 0.3% organically. Europe reported a 1.3% decline in organic sales triggered by flat to declining organic sales in all divisions but Merck Millipore, which achieved a 3.0% organic sales growth in the region. As a result, Europe’s contribution to Group sales decreased to 35% in the third quarter of 2012 (Q3 2011: 39%). Further softening economic conditions, pricing pressure in pharmaceuticals and uncertainty over the future of the Eurozone all weighed on the top-line.
| XLS |
|
Merck Group | Growth components by region – Q3 2012 | |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
€ million/change in % |
Sales |
Organic |
Exchange rate effects |
Acquisitions/ |
Reported |
|
Europe |
955.7 |
–1.3% |
0.9% |
0.3% |
– |
|
North America |
562.2 |
12.8% |
12.6% |
0.1% |
25.6% |
|
Emerging Markets |
964.0 |
12.0% |
6.9% |
– |
18.9% |
|
Rest of World |
239.8 |
0.3% |
8.3% |
0.2% |
8.8% |
|
Group |
2,721.7 |
5.9% |
5.7% |
0.2% |
11.8% |
Merck Group | Sales by region – Q3 2012
back
